Literature DB >> 30030581

Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math.

Frank A Giordano1, Marlon R Veldwijk2, Carsten Herskind2, Frederik Wenz2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30030581     DOI： 10.1007/s00066-018-1341-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  28 in total

1.  Reply: Immunosuppressive cell death in cancer.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2017-05-08       Impact factor: 53.106

2.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

3.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

Review 4.  Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies.

Authors:  Michael Rückert; Lisa Deloch; Rainer Fietkau; Benjamin Frey; Markus Hecht; Udo S Gaipl
Journal:  Strahlenther Onkol       Date:  2018-03-02       Impact factor: 3.621

Review 5.  Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies.

Authors:  B Frey; Y Rubner; R Wunderlich; E-M Weiss; A G Pockley; R Fietkau; U S Gaipl
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 7.  Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases.

Authors:  Benjamin Frey; Michael Rückert; Lisa Deloch; Paul F Rühle; Anja Derer; Rainer Fietkau; Udo S Gaipl
Journal:  Immunol Rev       Date:  2017-11       Impact factor: 12.988

8.  Ipilimumab and radiation therapy for melanoma brain metastases.

Authors:  Ann W Silk; Michael F Bassetti; Brady T West; Christina I Tsien; Christopher D Lao
Journal:  Cancer Med       Date:  2013-10-10       Impact factor: 4.452

Review 9.  Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection.

Authors:  Carsten Herskind; Frederik Wenz; Frank A Giordano
Journal:  Front Oncol       Date:  2017-07-24       Impact factor: 6.244

10.  Radiation as an immunological adjuvant: current evidence on dose and fractionation.

Authors:  Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-10-26       Impact factor: 6.244
View more
  4 in total

1.  Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.

Authors:  Theodore S Hong; Eliezer M Van Allen; Sophia C Kamran; Jochen K Lennerz; Claire A Margolis; David Liu; Brendan Reardon; Stephanie A Wankowicz; Emily E Van Seventer; Adam Tracy; Jennifer Y Wo; Scott L Carter; Henning Willers; Ryan B Corcoran
Journal:  Clin Cancer Res       Date:  2019-06-28       Impact factor: 12.531

2.  Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.

Authors:  Jaewon Hyung; Hyunseok Yoon; Chang-Min Choi; Shinkyo Yoon; Dae Ho Lee; Sang-We Kim; Hyeong-Ryul Kim; Su Ssan Kim; Si Yeol Song; Jae Cheol Lee
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-05       Impact factor: 4.322

Review 3.  Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art.

Authors:  Tiziana Feola; Francesca Carbonara; Monica Verrico; Rosa Maria Di Crescenzo; Francesca Gianno; Claudio Colonnese; Antonietta Arcella; Dario de Alcubierre; Silverio Tomao; Vincenzo Esposito; Felice Giangaspero; Giuseppe Minniti; Marie-Lise Jaffrain-Rea
Journal:  Cancers (Basel)       Date:  2022-08-24       Impact factor: 6.575

4.  PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study.

Authors:  Ymera Pignochino; Giovanni Crisafulli; Giorgia Giordano; Alessandra Merlini; Enrico Berrino; Maria Laura Centomo; Giulia Chiabotto; Silvia Brusco; Marco Basiricò; Elena Maldi; Alberto Pisacane; Valeria Leuci; Dario Sangiolo; Lorenzo D'Ambrosio; Massimo Aglietta; Bernd Kasper; Alberto Bardelli; Giovanni Grignani
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.